Abstract
The use of cytokines, especially interferon-α (IFN-α) and interleukin-2 (IL-2) to treat malignancies and chronic viral infections is broadening, and increasing attention is being paid to the effects of these agents on the central nervous system (CNS). It is now known that cytokine therapy can be associated with the development of cognitive and psychiatric adverse effects that range from subtle impairments of attention and memory undetectable on routine medical evaluation to delirium and psychosis. Because IFN-α is a highly effective therapy in certain diseases, it is important that patients continue on treatment at effective doses. Understanding the nature, incidence, severity, and mechanisms of CNS effects is essential to develop interventions to decrease morbidity while maintaining patients on treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amato, R., Meyers, C., Ellerhorst, J., Finn, L., Kilbourn, R., Sella, A., & Logothetis, C. (1995). A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma. Annals of Oncology, 6, 911–914.
Cummings, J. L. (1990). Subcortical Dementia. New York: Oxford University Press.
Dalakas, M. C., Mock, V., & Hawkins, M. J. (1998). Fatigue: definitions, mechanisms, and paradigms for study. Seminars in Oncology, 25Supplement 1, 48–53.
Goldman, L. S. (1994). Successful treatment of interferon alfa-induced mood disorder with nortriptyline (Letter to the editor). Psychosomatics, 35, 412–413.
Ho, B. T., Lu, J. G., Huo, Y. Y., Fan, S. H., Meyers, C. A., Tansey, L. W., Payne, R., & Levin, V. A. The opioid mechanism of interferon-α action. Anti-Cancer Drugs, 5, 90–94.
Jones, T. H. J., Wadler, S., & Hupart, K. H. (1998). Endocrine-mediate mechanisms of fatigue during treatment with interferon-α. Seminars in Oncology, 25Supplement 1, 54–63.
Levenson, J. L. & Fallon, H. J. (1993). Fluoxetine treatment of depression caused by interferon-alpha. American Journal of Gastroenterology, 88, 760–761.
Licinio, I, Kling, M. A., & Hauser, P. (1998). Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Seminars in Oncology, 25Supplement1, 30–38.
Mapou, R. L., Law, W. A., Wagner, K., Malone, J. L., & Skillman, D. R. (1996). Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 8, 74–81.
Meyers, C. A. & Abbruzzese, J. L. (1992). Cognitive functioning in cancer patients: effect of previous treatment. Neurology, 42, 434–436.
Meyers, C. A. & Valentine, A. D. (1995). Neurologic and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56–68.
Meyers, C. A., Valentine, A. D., Wong, F. C. L., & Leeds, N. E. (1994). Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 285–288.
Meyers, C. A. & Yung, W. K. A. (1993). Delayed neurotoxicity of intraventricular interleukin-2: a case report. Journal of Neuro-Oncology, 15, 265–267.
Meyers, C. A., Obbens, E. A. M. T., Scheibel, R. S., & Moser, R. P. (1991). Neurotoxicity of intraventricularly administered alpha interferon for leptomeningeal disease. Cancer, 68, 88–91.
Meyers, C. A., Scheibel, R. S., & Forman, A. D. (1991). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology, 41, 672–676.
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology, 45, 947–950.
Plata-Salaman, C. R. (1998). Cytokines and anorexia: a brief overview. Seminars in Oncology, 25Supplement 1, 64–72.
Smith, A., Tyrrell, D., Coyle, K., & Higgins, P. (1988). Effects of interferon alpha on performance in man: a preliminary study. Psychopharmacology, 96, 414–416
Strite, D., Valentine, A. D., & Meyers, C. A. (1997). Manic episodes in two patients treated with interferon alpha. Journal of Neuropsychiatry and Clinical Neurosciences, 9, 273–276.
Taylor, J. L. & Grossberg, S. E. (1998). The effects of interferon-α on the production and action of other cytokines. Seminars in Oncology, 25Supplement 1, 23–29.
Valentine, A. D., Meyers, C. A., & Talpaz, M. (1995). Treatment of neurotoxic side effects of interferon-α with naltrexone. Cancer Investigation, 13, 561–566.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-α therapy. Seminars in Oncology, 25Supplement 1, 39–47.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Kluwer Academic/Plenum Publishers
About this chapter
Cite this chapter
Meyers, C.A. (1999). Mood and Cognitive Disorders in Cancer Patients Receiving Cytokine Therapy. In: Dantzer, R., Wollman, E.E., Yirmiya, R. (eds) Cytokines, Stress, and Depression. Advances in Experimental Medicine and Biology, vol 461. Springer, New York, NY. https://doi.org/10.1007/978-0-585-37970-8_5
Download citation
DOI: https://doi.org/10.1007/978-0-585-37970-8_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46135-4
Online ISBN: 978-0-585-37970-8
eBook Packages: Springer Book Archive